Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CCMNASDAQ:OPGNNASDAQ:PIIINASDAQ:RNLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCCMConcord Medical Services$6.83-1.7%$6.34$3.80▼$12.70$29.67M-0.8418,091 shs2,192 shsOPGNOpGen$5.00+6.4%$4.59$0.53▼$5.25$50.34M-1.689,734 shs5,800 shsPIIIP3 Health Partners$6.42+1.1%$8.14$6.33▼$33.73$46.15M0.8420,265 shs7,240 shsRNLXRenalytix$0.21$0.23$0.18▼$2.40$17.18M2.721.45 million shs934,496 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCCMConcord Medical Services-2.46%-4.22%-6.55%+58.98%-3.86%OPGNOpGen+0.21%+3.30%-4.28%+291.67%+85.77%PIIIP3 Health Partners-3.20%-6.48%-22.66%-29.60%-80.17%RNLXRenalytix0.00%0.00%0.00%0.00%-55.69%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCCMConcord Medical Services1.3334 of 5 stars0.05.00.00.02.01.70.6OPGNOpGenN/AN/AN/AN/AN/AN/AN/AN/APIIIP3 Health Partners2.3848 of 5 stars3.34.00.00.02.20.80.6RNLXRenalytixN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCCMConcord Medical Services 0.00N/AN/AN/AOPGNOpGen 0.00N/AN/AN/APIIIP3 Health Partners 2.50Moderate Buy$16.25153.12% UpsideRNLXRenalytix 3.00Buy$3.001,348.58% UpsideCurrent Analyst Ratings BreakdownLatest RNLX, PIII, OPGN, and CCM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2025PIIIP3 Health PartnersLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$50.00 ➝ $20.00(Data available from 6/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCCMConcord Medical Services$383.96M0.08N/AN/A$56.67 per share0.12OPGNOpGen$2.67M18.83N/AN/A($11.55) per share-0.43PIIIP3 Health Partners$1.49B0.03$2.77 per share2.32$0.45 per share14.27RNLXRenalytix$2.29M7.50N/AN/A($0.10) per share-2.07Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCCMConcord Medical Services-$41.93MN/A0.00∞N/AN/AN/AN/AN/AOPGNOpGen-$32.67MN/A0.00∞N/A-1,140.36%N/A-287.58%7/7/2025 (Estimated)PIIIP3 Health Partners-$57.77M-$47.28N/AN/AN/A-6.95%-71.31%-11.93%8/6/2025 (Estimated)RNLXRenalytix-$33.46M-$0.39N/A∞N/A-1,461.60%N/A-281.40%N/ALatest RNLX, PIII, OPGN, and CCM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025PIIIP3 Health Partners-$5.00-$6.28-$1.28-$6.28$362.09 million$373.23 million3/27/2025Q4 2024PIIIP3 Health Partners-$8.50-$16.00-$7.50-$0.36$378.88 million$370.69 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCCMConcord Medical ServicesN/AN/AN/AN/AN/AOPGNOpGenN/AN/AN/AN/AN/APIIIP3 Health PartnersN/AN/AN/AN/AN/ARNLXRenalytixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCCMConcord Medical Services1.150.470.46OPGNOpGenN/A5.455.45PIIIP3 Health Partners1.110.530.53RNLXRenalytixN/A0.530.53Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCCMConcord Medical ServicesN/AOPGNOpGen2.68%PIIIP3 Health Partners7.75%RNLXRenalytix9.92%Insider OwnershipCompanyInsider OwnershipCCMConcord Medical Services46.50%OPGNOpGen43.80%PIIIP3 Health Partners17.79%RNLXRenalytix18.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCCMConcord Medical Services9704.34 million2.32 millionNot OptionableOPGNOpGen10010.07 million4.70 millionNot OptionablePIIIP3 Health Partners5007.19 million294.74 millionNot OptionableRNLXRenalytix10082.96 million63.06 millionOptionableRNLX, PIII, OPGN, and CCM HeadlinesRecent News About These CompaniesRenalytix shares gain as billable test numbers set new company recordApril 10, 2025 | proactiveinvestors.co.ukRenalytix Adjusts Share Capital Amid Fundraising ShortfallNovember 6, 2024 | markets.businessinsider.comRenalytix PLC (RNLX) Stock: Unveiling Its Hidden StrengthsOctober 2, 2024 | bovnews.comRenalytix PLC (RNLX) Stock: Surpassing Expectations in the Market?September 11, 2024 | bovnews.comWhat Factors Have Led to Renalytix PLC (RNLX) Stock Trading -90.00% Below Its 52-Week High?September 2, 2024 | bovnews.comThe Renalytix Plc ADR (RNLX) Stock expansion path aheadJuly 23, 2024 | bovnews.comRenalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansion for KidneyIntelX Platform Beyond USJuly 11, 2024 | globenewswire.comRenalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting DeterminationJune 27, 2024 | globenewswire.comMedicare Issues Final Coverage Determination for kidneyintelX.dkdJune 14, 2024 | globenewswire.comWhat do you think? Take A Moment To Read: Renalytix Plc ADR (RNLX) StockMay 27, 2024 | bovnews.comIs Renalytix Plc ADR (RNLX) Stock Paving the Way for Earnings?May 16, 2024 | bovnews.comRNLX Stock Earnings: Renalytix Misses EPS, Misses Revenue for Q3 2024May 15, 2024 | investorplace.comRenalytix AI GAAP EPS of -$0.08 beats by $0.01, revenue of $0.54M misses by $0.56MMay 15, 2024 | msn.comRenalytix Reports Financial Results for Third Quarter of Fiscal Year 2024May 15, 2024 | globenewswire.comRenalytix AI is about to announce its earnings — here's what Wall Street expectsMay 15, 2024 | markets.businessinsider.comRenalytix AI earnings: here's what Wall Street expectsMay 14, 2024 | markets.businessinsider.comRenalytix to Report Financial Results for Third Quarter Fiscal Year 2024 on May 15May 9, 2024 | finance.yahoo.comRenalytix to Report Financial Results for Third Quarter Fiscal Year 2024 on May 15May 9, 2024 | globenewswire.comRenalytix Plc (RNLX) Stock Price, News, Quote & History - Yahoo FinanceApril 28, 2024 | finance.yahoo.comRenalytix files to sell 19.99M ordinary shares for holdersApril 17, 2024 | msn.comMedia Sentiment Over TimeRNLX, PIII, OPGN, and CCM Company DescriptionsConcord Medical Services NYSE:CCM$6.83 -0.12 (-1.70%) Closing price 03:59 PM EasternExtended Trading$6.55 -0.28 (-4.13%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. It operates in two segments, Network and Hospital. The company's services include linear accelerators and external beam radiotherapy, proton therapy system, gamma knife radiosurgery, and diagnostic imaging services. Its other treatments and diagnostic services comprise positron emission tomography-computed tomography and magnetic resonance imaging scanners. In addition, the company provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, as well as helps to recruit and determine the compensation of doctors and other medical personnel. Further, it offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, the company operates specialty cancer hospitals, which offers radiation, imaging, test laboratory, inpatient, and nursing services. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, the People's Republic of China.OpGen NASDAQ:OPGN$5.00 +0.30 (+6.38%) As of 01:07 PM EasternOpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.P3 Health Partners NASDAQ:PIII$6.42 +0.07 (+1.10%) Closing price 04:00 PM EasternExtended Trading$6.42 0.00 (-0.08%) As of 04:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. P3 Health Partners Inc. was founded in 2020 and is based in Henderson, Nevada.Renalytix NASDAQ:RNLXRenalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix Plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; and Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why a Trump-Musk Feud Could Mean Big Wins for AST SpaceMobile Dave & Buster’s: Short-Covering Rally Signals Big Upside for PLAY GitLab: Buy It Low While You Still Can—Higher Prices Are Coming RKLB Breakout Fails Near Highs: Should Investors Be Concerned? Amazon Is on Track to Hit a Critical Level: Watch Out Tesla Stock: Why These 2 Downgrades Are Actually a Buy Signal Nintendo Stock Near Highs—Will the Switch 2 Keep the Rally Alive? Will Warner Bros. Discovery’s Split Produce Double the Upside? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
